Cancer immunotherapy — teaching the immune system to find and destroy tumours — is one of medicine's most promising frontiers. Checkpoint inhibitors, CAR-T cells, T cell therapies: the field has produced genuine miracles, patients whose terminal cancers vanished. But there's a problem that has blocked progress for years.
T cells get tired.
In the hostile environment inside a tumour, the immune cells that should be killing cancer cells become exhausted — they lose their effectiveness, slow down, stop working. Scientists call it 'T cell exhaustion,' and it's one of the main reasons immunotherapy works brilliantly in some patients and fails in others.
For years, researchers have known exhaustion happens. What they haven't known, in precise molecular detail, is exactly why — or what to do about it.
A study published in March 2026 by researchers at Memorial Sloan Kettering Cancer Center and collaborating institutions has identified a critical piece of that puzzle. The team discovered two previously unknown transcription factors — proteins that control how genes are read — called ZSCAN20 and JDP2. These factors, it turns out, actively drive the exhaustion programme in CD8+ T cells: the frontline killers of the immune system.
In experiments, the researchers disabled ZSCAN20 and JDP2 in exhausted CD8 T cells. The result: the cells' tumour-killing power was restored. Even better — long-term immune memory was preserved. The T cells didn't just get a short burst of renewed activity; they retained the ability to mount sustained responses.
This distinction matters enormously. Earlier strategies for reversing T cell exhaustion, including anti-PD-1 checkpoint inhibitors, can temporarily reinvigorate exhausted T cells — but the cells often become re-exhausted, and durable responses remain rare. If ZSCAN20 and JDP2 represent a more fundamental switch — one that governs whether a T cell enters the exhaustion programme at all — targeting them could lead to therapies that sustain immune responses over the long term.
The implications ripple out across oncology. CAR-T cell therapies, where patients' own T cells are genetically engineered and infused back to fight their cancer, are already an approved treatment for some blood cancers. But they struggle in solid tumours, partly because engineered T cells exhaust quickly in the tumour microenvironment. Programmes that disable ZSCAN20 and JDP2 during T cell engineering could change that calculus.
Checkpoint immunotherapy, already the backbone of treatment for melanoma, lung cancer, kidney cancer, and others, might also be made more effective by combining it with approaches that target these exhaustion genes.
'We've identified the genetic rules that govern whether a T cell fights or gives up,' the researchers noted in the accompanying commentary. 'That gives us a blueprint for building T cells that don't quit.'
The work adds to a wave of discoveries in early 2026 unpicking the precise molecular mechanisms behind T cell exhaustion — from metabolic reprogramming strategies to natural killer cell modifications. The picture that's emerging is of a complex, multi-layered exhaustion programme — one that may be disrupted at multiple points.
For the hundreds of thousands of patients each year for whom immunotherapy fails, these findings represent a real pathway forward. The immune system can fight cancer. Now we're learning exactly how to stop it giving up. 🧬